Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.26.1
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Net Loss $ 13,563,834 $ 11,850,118
Reportable Segment, Aggregation before Other Operating Segment [Member]    
Segment Reporting Information [Line Items]    
Preclinical, clinical trial and other costs 6,240,583 5,450,963
Research and development personnel expense [1] 1,569,754 1,818,183
General and administrative personnel expense [2] 2,786,832 1,981,756
Administrative and facilities expense [3] 3,391,336 2,800,304
Other income, net (424,671) (201,088)
Net Loss $ 13,563,834 $ 11,850,118
[1] Research and development personnel costs include employee stock-based compensation expense of $192,630 and $169,414 for the year ended December 31, 2025 and 2024, respectively.
[2] General and administrative personnel costs include employee stock-based compensation expense of $508,644 and $186,925 for the year ended December 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.
[3] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.